- Home
- FT vs RPID Comparison
FT vs RPID Comparison
Compare FT & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FT
- RPID
- Stock Information
- Founded
- FT 1988
- RPID 2006
- Country
- FT United States
- RPID United States
- Employees
- FT N/A
- RPID 163
- Industry
- FT Trusts Except Educational Religious and Charitable
- RPID Medical Specialities
- Sector
- FT Finance
- RPID Health Care
- Exchange
- FT Nasdaq
- RPID Nasdaq
- Market Cap
- FT 201.3M
- RPID 167.6M
- IPO Year
- FT N/A
- RPID 2021
- Fundamental
- Price
- FT $7.98
- RPID $3.69
- Analyst Decision
- FT
- RPID Strong Buy
- Analyst Count
- FT 0
- RPID 2
- Target Price
- FT N/A
- RPID $8.00
- AVG Volume (30 Days)
- FT 63.0K
- RPID 78.8K
- Earning Date
- FT 01-01-0001
- RPID 10-31-2025
- Dividend Yield
- FT 7.85%
- RPID N/A
- EPS Growth
- FT N/A
- RPID N/A
- EPS
- FT N/A
- RPID N/A
- Revenue
- FT N/A
- RPID $30,289,000.00
- Revenue This Year
- FT N/A
- RPID $16.63
- Revenue Next Year
- FT N/A
- RPID $21.98
- P/E Ratio
- FT N/A
- RPID N/A
- Revenue Growth
- FT N/A
- RPID 22.57
- 52 Week Low
- FT $5.97
- RPID $0.83
- 52 Week High
- FT $7.23
- RPID $4.50
- Technical
- Relative Strength Index (RSI)
- FT 54.95
- RPID 67.33
- Support Level
- FT $7.97
- RPID $3.11
- Resistance Level
- FT $8.08
- RPID $3.38
- Average True Range (ATR)
- FT 0.09
- RPID 0.27
- MACD
- FT 0.00
- RPID 0.06
- Stochastic Oscillator
- FT 65.52
- RPID 78.42
About FT Franklin Universal Trust
Franklin Universal Trust is a closed-end management investment company. Its primary investment objective is to provide high, current income consistent with the preservation of capital. Its secondary objective is the growth of income through dividend increases and capital appreciation. The fund invests in two asset classes being the high yield bonds and utility stocks.
About RPID Rapid Micro Biosystems Inc.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.